


Viral load at delivery in about 13 percent of women taking HAART

January 20 2015



(HealthDay)—Among women who initiate highly-active antiretroviral therapy (HAART) during pregnancy, 13.1 percent have detectable viral load (VL) at delivery, according to a study published online in the Jan. 20 issue of the *Annals of Internal Medicine*.

Ingrid T. Katz, M.D., from Brigham and Women's Hospital in Boston, and colleagues examined the factors associated with detectable VL at delivery, despite initiation of HAART during [pregnancy](#), in a multicenter observational study. Data were included for 671 [women](#) from 67 U.S. AIDS clinical research sites between 2002 and 2011.

The researchers found that 13.1 percent of the women had detectable VL at delivery. Multiparity (P = 0.002); black ethnicity (versus Hispanic or white; P

"Social factors, including ethnicity and education, may help identify women who could benefit from focused efforts to promote early HAART initiation and adherence," the authors write.

More information: [Full Text \(subscription or payment may be required\)](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: Viral load at delivery in about 13 percent of women taking HAART (2015, January 20) retrieved 25 April 2024 from <https://medicalxpress.com/news/2015-01-viral-delivery-percent-women-haart.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.